Caso Clínico Enrique Grande Head of Medical Oncology

Slides:

Advertisements

Similar presentations

Months of the year December January November October February

Advertisements

Neoadjuvant Chemotherapy in Malignant Peripheral Nerve Sheath Tumors Elizabeth Shurell, M.D., M.Phil. UCLA General Surgery Resident Research Fellow, Division.

Michele Milella Oncologia Medica A Istituto Nazionale Tumori Regina Elena Roma.

Chubaka Producciones Presenta :.

2012 JANUARY Sun Mon Tue Wed Thu Fri Sat

P Pathophysiology Calendar. SundayMondayTuesdayWednesdayThursdayFridaySaturday January 2012.

Savings and Investment Unit Project Student Name.

WORD JUMBLE. Months of the year Word in jumbled form e r r f b u y a Word in jumbled form e r r f b u y a february Click for the answer Next Question.

DATE POWER 2 INCOME JANUARY 100member X 25.00P2, FEBRUARY 200member X 25.00P5, MARCH 400member X 25.00P10, APRIL 800member.

2011 Calendar Important Dates/Events/Homework. SunSatFriThursWedTuesMon January

Raafat R. Abdel-Malek, MD, FRCR Ass. Prof Clinical Oncology Cairo University, Egypt Efficacy & Toxicity of Sunitinib in mRCC patients in Egypt.

1 First interim results of GIDEON: oncologists and non-oncologists appear to use sorafenib differently Alan P Venook, MD University of California, San.

July 2007 SundayMondayTuesdayWednesdayThursdayFridaySaturday

MA.17R: Reduced Risk of Recurrence With Extending Adjuvant Letrozole Beyond 5 Yrs in Postmenopausal Women With Early-Stage Breast Cancer CCO Independent.

Risk Stratification in Stage II Colon Cancer Patients Ramzi Amri, MD, PhD; Liliana G Bordeianou, MD, MPH; and David L Berger, MD Massachusetts General.

Angelo Di Leo “Sandro Pitigliani” Medical Oncology Department Hospital of Prato Istituto Toscano Tumori, Prato, Italy Adjuvant hormone therapy in pre-menopausal.

Phase I/II CheckMate 032: Nivolumab ± Ipilimumab in Advanced SCLC

Over 1,000 robotic surgeries performed to date, and counting

: Mogamulizumab in R/R Adult T-Cell Leukemia-Lymphoma

Volume 60, Issue 5, Pages (November 2011)

Management of Metastatic Renal Cell Carcinoma

Lymph Node Dissection for Renal Cell Carcinoma: When, How and Why?

Pazopanib: the role in the treatment of mRCC

Aspirin Associated With Reduced Mortality in Patients With CRC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 - June 2,

ASPEN: Prolonged PFS With Sunitinib vs Everolimus in Nonclear-Cell RCC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* May 29 -

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

#BlackHealthMatters: Improving Breast Cancer Outcomes for Black Women

Final results of the phase III, randomised, double-blind AVOREN trial of first-line bevacizumab + interferon-a2a in metastatic renal cell carcinoma Escudier.

PUBLISH ONLY Journal of Thoracic Oncology

Dictation practice 2nd Form Ms. Micaela-Ms. Verónica.

McDonald’s Kalender 2009.

McDonald’s Kalender 2009.

Mahmood rasheed Hematology/oncology fellow VCU Massey cancer center

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

1 1.テキストの入れ替えテキストを自由に入れ替えることができます。フチなし全面印刷がおすすめです。印刷のポイント.

January MON TUE WED THU FRI SAT SUN

January MON TUE WED THU FRI SAT SUN

2017/18 Payment Calendar Due Date Cut-off Day 1st of every month

McDonald’s Kalender 2009.

January MON TUE WED THU FRI SAT SUN

January MON TUE WED THU FRI SAT SUN

A Clinical Prognostic Index for Patients Treated with Erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 Marie Florescu,

0845 Analysis I have only very recently taken over responsibility for the 0845 number and whilst questions were asked of Derrick some months ago, we have.

Problem Gambling Clicks to Opgr.org

2300 (11PM) September 21 Blue line is meridian..

Domenica 03 giugno Highlight a cura di Filippo de Marinis

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

Frank Detterbeck, MD Journal of Thoracic Oncology

McDonald’s calendar 2007.

Meta-analysis of randomised phase III clinical trials with ALK inhibitors in non-small cell lung cancer (NSCLC) showing similar benefit in male patients.

1 - January - Sun Mon The Wed Thu Fri Sat

Teacher name August phone: Enter text here.

JANUARY 1 Sun Mon Tue Wed Thu Fri Sat

JANUARY 1 Sun Mon Tue Wed Thu Fri Sat

PUBLISH ONLY Journal of Thoracic Oncology

Prognostic Models to Predict Survival in Non–Small-Cell Lung Cancer Patients Treated with First-Line Paclitaxel and Carboplatin with or without Bevacizumab

Richard J Gralla, MD, Frank Griesinger, MD, PhD

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

JANUARY 1 Sun Mon Tue Wed Thu Fri Sat

Redefiniendo el Tratamiento del Cáncer Renal

McDonald’s calendar 2007.

Rol de la IO en el Tratamiento del Cáncer Renal: CheckMate 214

TITLE & AUTHORS Presenter Name, Institution, Country.

Habitat Changes and Fish Migration

January Monday Tuesday Wednesday Thursday Friday Saturday Sunday 30 31

Kaplan-Meier plots of (A) time to first improvement and (B) time to first deterioration in pain in the chest, cough and dyspnoea, according to the 13-Item Quality.

2015 January February March April May June July August September

Habitat Changes and Fish Migration

Venn diagram for degree of overlap of 158 candidate prognostic genes.

Presentation transcript:

Caso Clínico Enrique Grande Head of Medical Oncology Director of Clinical Research

Disclosures Honoraria for ad boards and/or lectures: Pfizer, BMS, IPSEN, Roche, Eisai, Eusa Pharma, MSD, Sanofi-Genzyme, Adacap, Novartis, Pierre Fabre, Lexicon, Celgene Research Grants: Pfizer, Astra Zeneca, MTEM/Threshold, Roche, IPSEN, Lexicon Leadership roles in medical societies: ENETS, GETNE and GETHI Stocks or ownership interest: None

Real Cases

Our own experience with NIVO + IPI in 1st Line mRCC with poor risk component June 2016 October 2016 November 2016 65 y.o. woman Nephrectomy due to left kidney primary tumor in 2013 ECOG 2 (pain, haemoptysis, dyspnoea) Hb 10.6 g/ml LDH 1.239 Recruited for CheckMate 214 trial Started Nivo+IPI in July 2016 Enrique Grande. *unpublished data

Our own experience with NIVO + IPI in 1st Line mRCC with sarcomatoid component March 2016 August 2016 March 2017 60 y.o. male Nephrectomy due to left kidney primary tumor in February 2016 Sarcomatoid 35% component Recruited for CheckMate 214 trial Started NIVO + IPI in May 2016 Enrique Grande. *unpublished data

Case scenarios

Patient profile 77 y.o. Lung and lymph nodes metastasis ECOG 1 Recently diagnosed 2 adverse prognostic factors by Heng`s score Adapted from Grande E, et al. World J Clin Oncol 2017

Patient profile 77 y.o. Lung and lymph nodes metastasis ECOG 1 Recently diagnosed 2 adverse prognostic factors by Heng`s score 41 y.o. Lung and lymph nodes metastasis ECOG 1 Recently diagnosed 2 adverse prognostic factors by Heng`s score Adapted from Grande E, et al. World J Clin Oncol 2017

Tumor Volume Adapted from Grande E, et al. World J Clin Oncol 2017

Intermediate-risk group mostly comprised of three subgroups MSKCC IMDC 1 risk factor: 59% 2 risk factors: 41% 1 risk factor: 59% 2 risk factors: 41% Low serum Hg 16.4% Low serum Hg 13.3% Low serum Hg & <1 year from Dx to Tx 29.4% Low serum Hg & <1 year from Dx to Tx 24.6% <1 year from Dx to Tx 36.0% <1 year from Dx to Tx 38.3% Sella A, et al. Clin Genitourin Cancer 2018

egrande@mdanderson.es @drenriquegrande